All the Drug Class Drugs
Janus Kinase Inhibitor (JAKs). Tofacitinib 5 mg. F.C. TAB: 28, 60, 180. Rheum. Arthrit: The drug may be used as monotherapy/in combin. with methotrexate or other non-biologic dis. modif. antirheum. drugs (DMARDs): 5 mg×2/d dly. oral. with/without food.
Psoriat. Arthrit: 5 mg×2/d dly. oral. with/without food, used in comb. with non-biologic DMARDs. The efficacy of Tofacitinib as a monother. has not been studied in psoriat. arthritis.
UC: 10 mg×2/d for at least 8 wks.; follow. by 5/10 mg×2/d, depend. on therapeut. response. Use the lowest effective dose to maint. response. Discont. Tofacitinib after 16 wks. of tmt. with 10 mg×2/d, if adequate therap. benefit is not achieved See lit.
Rheum. Arthrit: Indic. for the tmt. of adult. pts. with moderat. to sev. active RA who have had an inadeq. response or intolerance to methotrexate. It may be used as mono-ther. or in comb. with methotrexate/other non-biolog. DMARDs.
Limitations of Use: Use of Tofacitinib in comb. with biologic DMARDs or with potent immune-suppressant. such as azathioprine & cyclosporine is not recomm.
Psoriat. Arthrit.: Indicated for the tmt. of adult pts. with active psoriat. arthrit. who have had an inadeq. response or intoleran. to methotrexate or other DMARDs.
Limitations of Use: Use of Tofacitinib in comb. with biologic DMARDs or with potent immune-suppressant. such as azathioprine & cyclosporine is not recomm.
Ulcerat. colitis: Tmt. of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intoler. to either convent. ther. or a biologic agent.
Limitations of Use: Use of Tofacitinib in comb. with biology. therap. for UC or with potent immunosuppress. such as azathioprine and cyclosporine is not recomm.
C/I: Hypersens.
